Page 1,915«..1020..1,9141,9151,9161,917..1,9201,930..»

Paul Allen gives 100 million to explore how cells work

Posted: December 9, 2014 at 7:51 am

SEATTLE After tackling the brain, the Ebola epidemic, and a host of other issues, billionaire Paul Allen has a new target for scientific philanthropy: unraveling the inner workings of human cells.

On Monday, the Microsoft co-founder announced a $100 million, five-year grant to establish the Allen Institute for Cell Science in Seattle.

The goal is to better understand the teeming world inside cells, where thousands of organelles and millions of molecules interact in a dynamic ballet that researchers are just beginning to fathom.

We really dont have a good idea of how normal cells work, and what goes wrong in disease, said Rick Horwitz, the former University of Virginia professor who jumped at the chance to lead the new institute. People spend careers trying to understand little parts of the cell, but nobody has stitched it together because its too complicated for any individual to study.

The institute will take on the challenge by combining new technologies, like microscopes that can visualize living cells in three dimensions, with enough computational firepower to make sense of the flood of data that will result, Horwitz said.

Eventually, he and his team hope to develop computer models that mimic living cells. If they succeed, those models could also shed light on what goes haywire in cancer and other diseases and help develop cures, he said.

At a time when federal research budgets are shrinking, the announcement is one of the most exciting things to happen in Seattle science in a long time, said Dr. Chuck Murry, co-director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington. When the Allen folks get into something, they do it at a scale thats just mind-blowing.

The grant is one of Allens largest, on par with the $100 million he committed earlier this year to fight Ebola in West Africa, and a $100 million grant in 2003 to establish the Seattle-based Allen Institute for Brain Science. He has since plowed an additional $300 million into the brain institute.

Allen, who joined his old partner Bill Gates in pledging to donate the bulk of his wealth, has stepped up his philanthropic efforts in recent years. Its a good bet he will continue investing in the cell institute as long as it measures up, said Allan Jones, who leads the Allen Institute for Brain Science and helped organize its new sister institute.

We need to knuckle down and show that we can deliver something very powerful, Jones said.

See the rest here:
Paul Allen gives 100 million to explore how cells work

Posted in West Virginia Stem Cells | Comments Off on Paul Allen gives 100 million to explore how cells work

Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant

Posted: December 9, 2014 at 7:51 am

Seattle After tackling the brain, the Ebola epidemic, and a host of other issues, billionaire Paul Allen has a new target for scientific philanthropy: unraveling the inner workings of human cells.

On Monday, the Microsoft co-founder announced a $100 million, five-year grant to establish the Allen Institute for Cell Science in Seattle.

The goal is to better understand the teeming world inside cells, where thousands of organelles and millions of molecules interact in a dynamic ballet that researchers are just beginning to fathom.

We really dont have a good idea of how normal cells work, and what goes wrong in disease, said Rick Horwitz, the former University of Virginia professor who jumped at the chance to lead the new institute. People spend careers trying to understand little parts of the cell, but nobody has stitched it together because its too complicated for any individual to study.

The institute will take on the challenge by combining new technologies, like microscopes that can visualize living cells in three dimensions, with enough computational firepower to make sense of the flood of data that will result, Horwitz said.

Eventually, he and his team hope to develop computer models that mimic living cells. If they succeed, those models could also shed light on what goes haywire in cancer and other diseases and help develop cures, he said.

At a time when federal research budgets are shrinking, the announcement is one of the most exciting things to happen in Seattle science in a long time, said Dr. Chuck Murry, co-director of the Institute for Stem Cell and Regenerative Medicine at the University of Washington. When the Allen folks get into something, they do it at a scale thats just mind-blowing.

The grant is one of Allens largest, on par with the $100 million he committed earlier this year to fight Ebola in West Africa, and a $100 million grant in 2003 to establish the Seattle-based Allen Institute for Brain Science. He has since plowed an additional $300 million into the brain institute.

Allen, who joined his old partner Bill Gates in pledging to donate the bulk of his wealth, has stepped up his philanthropic efforts in recent years. Its a good bet he will continue investing in the cell institute as long as it measures up, said Allan Jones, who leads the Allen Institute for Brain Science and helped organize its new sister institute.

We need to knuckle down and show that we can deliver something very powerful, Jones said.

The rest is here:
Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant

Posted in West Virginia Stem Cells | Comments Off on Microsoft Co-Founder Establishes Cell Institute with $100 Million Grant

Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients

Posted: December 9, 2014 at 7:51 am

PUBLIC RELEASE DATE:

6-Dec-2014

Contact: Amanda Szabo aszabo@hematology.org 415-978-3620 American Society of Hematology @ASH_hematology

(SAN FRANCISCO, December 6, 2014) - New treatment combinations and targeted therapies for lymphoma and multiple myeloma are improving outcomes for vulnerable patient populations with hard-to-treat disease, according to studies presented today at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition.

Despite advances in lymphoma treatments, improving the prognosis for patients with relapsed and treatment-resistant disease remains a challenge. The early success of several precision therapies associated with fewer side effects than conventional approaches offers new hope for conquering aggressive disease. For lymphoma patients who relapse or do not respond to initial therapy, stem cell transplantation also presents a potentially curative option; however, this procedure is not always successful. Two studies presented today detail methods to improve outcomes in patients with relapsed or hard-to-treat lymphoma, including adding a targeted antibody to standard treatment to prevent relapse after transplant, and an approach to making stem cell transplantation the standard of care for patients with HIV-associated lymphoma.

In three other studies, researchers will describe new advances in the treatment of myeloma. These reports are examples of new precision treatments, including a proteasome inhibitor and two anti-CD28 antibodies that demonstrate encouraging results when combined with standard care for patients with relapsed and treatment-resistant disease.

"While eradicating aggressive lymphoma and multiple myeloma remains a major hurdle, the emergence of several promising strategies makes this an exciting time for physician-scientists in this field," said Brad Kahl, MD, moderator of the press briefing and Associate Professor of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison. "By combining therapies and studying outcomes in vulnerable subsets of patients, we are learning more about how we can best help those who have not responded to any other treatment."

This press briefing will take place at 8 a.m. PST on Saturday, December 6, in rooms 236-238 of Moscone South, East Mezzanine.

Brentuximab Vedotin Prolongs Post-Transplant Survival in Hard-to-Treat Lymphoma Patients in Phase III Study

The AETHERA Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma Study [673]

Read more:
Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients

Posted in Wisconsin Stem Cells | Comments Off on Advances in lymphoma and multiple myeloma treatment seek to improve outcomes for patients

VQ 2014 Toronto – Stem Cell Research: Hype vs. Hope – Video

Posted: December 9, 2014 at 1:49 am


VQ 2014 Toronto - Stem Cell Research: Hype vs. Hope
Stem cell researcher Dr. Brian Ballios will talk about the potential of stem-cell derived therapies to restore sight, and the early trials now beginning in t...

By: FFBCanada

Link:
VQ 2014 Toronto - Stem Cell Research: Hype vs. Hope - Video

Posted in Stem Cell Research | Comments Off on VQ 2014 Toronto – Stem Cell Research: Hype vs. Hope – Video

Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells

Posted: December 8, 2014 at 9:47 am

Irvine, California (PRWEB) December 08, 2014

The Ageless Derma skin care company has added a moisturizing product to their line that provides continuous hydration to skin throughout the day. The Swiss Apple Stem Cell Oil-Free Continuous Moisturizer uses rare Swiss apple stem cells in combination with other natural substances to aid in skins retention of moisture for a lessening of fine lines and a silky, more comfortable feeling.

The Swiss Apple Stem Cell Oil-Free Continuous Moisturizer contains stem cells from the exotic Malus Domestica, a rare apple from Switzerland known for its long shelf life and its ability to stay fresh without shriveling. This apple species had a flavor that consumers found too acidic, making farmers reluctant to grow it. The Malus Domestica, however, was discovered to have interesting scientific advantages due to its ability to live a long, healthy life without the usual shriveling that accompanies fruit as it ages. The same idea has been transferred to Ageless Dermas latest moisturizer with its incorporation of these stem cell extracts for a renewed and rejuvenated facial complexion. The stem cells help with not only apple longevity, but also with repairing human skin cells. This results in the ultimate reduction of fine lines and wrinkles with regular use.

Other ingredients are added to the Swiss Apple Stem Cell Oil-Free Continuous Moisturizer to make this moisturizer a workhorse of anti-aging and hydrating skin renewal. Ceramides and essential fatty acids account for maximum skin hydration and strengthening of the skin barrier function. Capric Triglycerides silken skin, glycerin keeps moisturization and hydration in balance, and Ceramides 3, 611, and 1 (all lipids) stop moisture from escaping and hold the skin barrier intact. Swiss Apple Stem Cell Oil-Free Continuous Moisturizer also has sodium hyaluronate to attract and keep moisture in. The hyaluronate also aids in blood microcirculation and the smoothing of wrinkles.

The developers at Ageless Derma Skin Care know they are making something extraordinary happen. Their line of physician-grade skin care products incorporates an important philosophy: supporting overall skin health by delivering the most cutting-edge biotechnology and pure, natural ingredients to all of the skin's layers. This attitude continues to resonate to this day with the companys founder, Dr. Farid Mostamand, who nearly ten years ago began his journey to deliver the best skin care alternatives for people who want to have healthy and beautiful looking skin at any age. About this latest Ageless Derma product, Dr. Mostamand says, The Swiss Apple Stem Cell Oil-Free Continuous Moisturizer is a multi-beneficial product that protects skin and works to smooth lines and wrinkles as it keeps moisture in, working throughout the entire day. Without the correct distribution of moisture, skin becomes dry and susceptible to wrinkling. This product is oil-free and can be used for any skin type.

Ageless Derma products are formulated in FDA-approved Labs. All ingredients are inspired by nature and enhanced by science. Ageless Derma products do not contain parabens or any other harsh additives, and they are never tested on animals. The company has developed five unique lines of products to address any skin type or condition.

Read more:
Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells

Posted in Stem Cells | Comments Off on Ageless Derma Launches Its Latest Moisturizing Product Featuring Exotic Apple Stem Cells

New Preclinical Data of Tragaras TG02 in Acute Leukemia to be Presented at ASH 2014 Annual Meeting

Posted: December 8, 2014 at 9:47 am

San Diego, California (PRWEB) December 06, 2014

Tragara Pharmaceuticals, Inc. today announced that a poster on TG02, the Company's unique oral multi-kinase inhibitor, will be presented at the American Society of Hematology (ASH) 2014 Annual Meeting (December 6-9, 2014) in San Francisco.

Researchers from the Weill Medical College of Cornell University will present a poster entitled In Vivo Treatment With TG02 Results in Increased Mobilization and Sensitization of Leukemia Stem Cells to Chemotherapeutic Agents. In acute leukemia, leukemic stem cells comprise a largely quiescent, highly chemotherapy-resistant cell population that contributes to the initiation, propagation and relapse of the disease. The data show that TG02 induces an effect on leukemic stem cells, or their niche, that results in their mobilization to the periphery. Furthermore, the addition of cytarabine to TG02 produced a significant decrease in both marrow and peripheral blood leukemia cells, suggesting that treatment with TG02 may sensitize these typically chemotherapy-resistant cells to chemotherapy. The poster (#3765) will be shown on Monday, December 8, 2014, from 6:00PM - 8:00PM in the North Hall of Building E of the Moscone Center.

Based on the results of this research, the Company is in discussions with MD Anderson Cancer to design a clinical study to evaluate the activity of TG02 in combination with a hypomethylating agent in patients with acute myeloid leukemia. The study will be conducted by MD Anderson with support from Tragara.

The difficulty of eliminating quiescent leukemic stems cells with existing cancer agents has been a significant obstacle in the advancement of treatment options for acute leukemia patients, said Elias Jabbour, M.D. Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center. The preclinical data observed with TG02 is very encouraging and I am eager to see this research duplicated in the clinic.

About TG02 TG02 is a unique, oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin dependent kinases (CDKs) equipotently with JAK2, FLT3, and ERK5 inhibition. TG02 exerts its antitumor activity primarily via its potent CDK9 inhibition, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis of a wide range of tumor cells. TG02 development will initially focus on the treatment of hematologic malignancies, including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), based on the consistent anti-tumor activity that has been observed across a broad spectrum of hematologic cancer models, including those resistant to currently available therapies. In these models, TG02 demonstrated both single agent activity and synergy when administered with current standard of care therapies. Subsequent development will focus on an important group of solid tumors with unmet medical need, such as small cell lung cancer, triple negative breast cancer, and melanoma, which will also benefit from this mechanism of action, complemented with the benefits of inhibiting both JAK2 and ERK5, and depleting other CDK9-dependent proteins such as c-MYC and VEGF. These pathways affect disease progression and survival in hematologic malignancies and solid tumors.

TG02 is currently being evaluated in two separate phase I clinical trials in patients with MM and CLL in the United States.

About Tragara Tragara Pharmaceuticals, Inc. is a privately held pharmaceutical company based in San Diego, California. The company is focused on the clinical and commercial development of proprietary medicines for the treatment of cancer. TG02 is a unique, oral multi-kinase inhibitor which combines the benefits of inhibiting important cyclin dependent kinases equipotently with JAK2, FLT3, and ERK5 inhibition. TG02 exerts its antitumor activity via its potent CDK9 inhibition, which leads to the depletion of key survival proteins, such as Mcl-1, resulting in p53-independent apoptosis of a wide range of tumor cells. Tragara is managed by a team of entrepreneurs with both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. Its investors include: Domain Associates, Mitsubishi International Corporation, Morgenthaler Ventures, ProQuest Investments and RusnanoMedInvest.

Tragara strives to provide much-needed therapies that will contribute to patient health through better survival and an increase in the quality of life. For more information, visit http://www.tragarapharma.com.

Read the original here:
New Preclinical Data of Tragaras TG02 in Acute Leukemia to be Presented at ASH 2014 Annual Meeting

Posted in Stem Cells | Comments Off on New Preclinical Data of Tragaras TG02 in Acute Leukemia to be Presented at ASH 2014 Annual Meeting

Asymmetrex – Video

Posted: December 8, 2014 at 9:41 am


Asymmetrex
Technologies For Stem Cell Medicine.

By: Asymmetrex

See the article here:
Asymmetrex - Video

Posted in Cell Medicine | Comments Off on Asymmetrex – Video

Improved case of Anky Spondy after PRP and Stem Cell Therapy – Video

Posted: December 8, 2014 at 9:40 am


Improved case of Anky Spondy after PRP and Stem Cell Therapy
stem cell india, stem cell therapy india, stem cell in india, stem cell therapy in india, india stem cell, india stem cell therapy.

By: Stem Cell India

Read the rest here:
Improved case of Anky Spondy after PRP and Stem Cell Therapy - Video

Posted in Cell Therapy | Comments Off on Improved case of Anky Spondy after PRP and Stem Cell Therapy – Video

Future of Care: The Future of Stem Cell Therapy (Full Presentation) – Video

Posted: December 8, 2014 at 9:40 am


Future of Care: The Future of Stem Cell Therapy (Full Presentation)
Watch our October 29, 2014 Future of Care presentation on the future of stem cell therapy featuring Dr. David Brenner, Vice Chancellor, UC San Diego Health Sciences, Paul Viviano, Chief Executive...

By: UCSDHSDEV

See the original post here:
Future of Care: The Future of Stem Cell Therapy (Full Presentation) - Video

Posted in Cell Therapy, Stem Cell Therapy | Comments Off on Future of Care: The Future of Stem Cell Therapy (Full Presentation) – Video

Future of Care: The Future of Stem Cell Therapy Highlights – Video

Posted: December 8, 2014 at 9:40 am


Future of Care: The Future of Stem Cell Therapy Highlights
A few highlights from our October 29, 2014 Future of Care: Future of Stem Cell Therapy event featuring UC San Diego Health System CEO Paul Viviano, Director ...

By: UCSDHSDEV

Go here to see the original:
Future of Care: The Future of Stem Cell Therapy Highlights - Video

Posted in Cell Therapy | Comments Off on Future of Care: The Future of Stem Cell Therapy Highlights – Video

Page 1,915«..1020..1,9141,9151,9161,917..1,9201,930..»